Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

被引：3
作者：
Zhao, Menglu [1 ]
Yan, Chun-Yan [1 ]
Wei, Ya-Nan [1 ]
Zhao, Xi-He [1 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Clin Oncol, Shenyang 110022, Peoples R China
来源：
ANTIVIRAL RESEARCH | 2023年 / 219卷
基金：
中国国家自然科学基金;
关键词：
PD-L1; Drug resistance; Bispecific antibody; Antibody drug conjugate (ADC); TUMOR MUTATIONAL BURDEN; T-CELLS; ANTITUMOR IMMUNITY; CANCER; IMMUNOTHERAPY; BLOCKADE; EFFICACY; RECEPTOR; PD-L1; EXPRESSION;
D O I：
10.1016/j.antiviral.2023.105720
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/ PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapyresistant cancer.
引用
收藏
页数：11
相关论文
共 50 条
  • [31] Immune Checkpoint Inhibitors
    Haanen, John B. A. G.
    Robert, Caroline
    IMMUNO-ONCOLOGY, 2015, 42 : 55 - 66
  • [32] Immune checkpoint inhibitors for cancer treatment
    Park, Junsik
    Kwon, Minsuk
    Shin, Eui-Cheol
    ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (11) : 1577 - 1587
  • [33] The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors
    Takkenkamp, Tim J.
    Jalving, Mathilde
    Hoogwater, Frederik J. H.
    Walenkamp, Annemiek M. E.
    ENDOCRINE-RELATED CANCER, 2020, 27 (09) : E329 - E343
  • [34] Thymic tumors and immune checkpoint inhibitors
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1509 - S1515
  • [35] The gut microbiota and immune checkpoint inhibitors
    Humphries, Audrey
    Daud, Adil
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (09) : 2178 - 2182
  • [36] Hallmarks of Resistance to Immune-Checkpoint Inhibitors
    Karasarides, Maria
    Cogdill, Alexandria P.
    Robbins, Paul B.
    Bowden, Michaela
    Burton, Elizabeth M.
    Butterfield, Lisa H.
    Cesano, Alessandra
    Hammer, Christian
    Haymaker, Cara L.
    Horak, Christine E.
    McGee, Heather M.
    Monette, Anne
    Rudqvist, Nils-Petter
    Spencer, Christine N.
    Sweis, Randy F.
    Vincent, Benjamin G.
    Wennerberg, Erik
    Yuan, Jianda
    Zappasodi, Roberta
    Lucey, Vanessa M. Hubbard
    Wells, Daniel K.
    LaVallee, Theresa
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (04) : 372 - 383
  • [37] Resistance to immune checkpoint inhibitors in gastric cancer
    Liu, Kai
    Yuan, Shiman
    Wang, Chenyu
    Zhu, Hong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
    Qu, Jialin
    Jiang, Man
    Wang, Li
    Zhao, Deze
    Qin, Kang
    Wang, Yun
    Tao, Junyan
    Zhang, Xiaochun
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 127
  • [39] Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
    Cejuela, Monica
    Vethencourt, Andrea
    Pernas, Sonia
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1801 - 1819
  • [40] Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
    Zeng, Zhu
    Yang, Biao
    Liao, Zheng-Yin
    ONCOLOGY LETTERS, 2020, 20 (04)
12345